Roughly **1.3 billion people** worldwide have high blood pressure. Most can manage it with existing medicines. But for an estimated **10 to 20 percent** of those — well over 100 million people globally — nothing works well enough. They take two, three, sometimes four different blood pressure medications, and their numbers still don't come down.
For decades, medicine has had no real new answer for them. That may be about to change.
**What Makes Baxdrostat Different**
Baxdrostat, developed by **AstraZeneca** (acquired through its $1.8 billion purchase of CinCor Pharma in 2023), works by doing something no approved blood pressure drug does: it selectively blocks the production of **aldosterone**, a hormone made by the adrenal glands that tells the kidneys to retain salt and water. When aldosterone levels are elevated — which is the case in a significant subset of people with treatment-resistant hypertension — blood pressure rises and stays high regardless of other medications.
Existing drugs can block the *effects* of aldosterone downstream. Baxdrostat shuts off the factory. It's the first aldosterone synthase inhibitor to reach this stage of regulatory review, and the results from clinical trials are striking.
**The Trial Results**
In the Phase 3 **BaxHTN trial**, patients with uncontrolled or treatment-resistant hypertension received either baxdrostat or placebo on top of their existing medications. After 12 weeks:
- The **1 mg dose** of baxdrostat reduced systolic blood pressure by **8.7 mmHg** more than placebo - The **2 mg dose** delivered a **9.8 mmHg** reduction
In a separate Phase 3 **Bax24 trial** measuring 24-hour blood pressure, the reduction climbed to **14 mmHg** — a number that cardiologists describe as clinically profound.
To understand why that matters: a **5 mmHg reduction** in systolic blood pressure is estimated to lower the risk of stroke by about 13% and heart disease by about 9%. A 14 mmHg drop — in people who had already failed multiple medications — represents a genuinely transformative outcome.
Nearly **40% of patients** on baxdrostat reached target systolic blood pressure below 130 mmHg. Fewer than 20% on placebo did.
**Beyond Blood Pressure: Protecting the Kidneys**
High blood pressure and kidney disease are deeply intertwined — each makes the other worse. A Phase 2 trial involving patients with both hypertension and kidney disease found that baxdrostat reduced albumin in the urine (a key marker of kidney damage) by **55% compared to placebo**. This suggests the drug may not only lower blood pressure but actively slow the progression of kidney disease — one of the most serious and expensive complications of long-term hypertension.
For the millions of patients whose hypertension is damaging their kidneys even as existing drugs fail to bring their pressure under control, this secondary benefit could be significant.
**Where Things Stand**
AstraZeneca submitted a **New Drug Application (NDA)** to the FDA in late 2025. The FDA accepted it for **Priority Review** — a designation reserved for drugs that treat serious conditions and offer potential substantial improvement over available therapies. A regulatory decision is anticipated in **Q2 2026**.
If approved, baxdrostat would become the **first drug in its class** — the first aldosterone synthase inhibitor ever authorised for clinical use. It would not replace existing blood pressure medications but complement them, offering a new option for the patients current medicines have failed.
**The People This Could Help**
Treatment-resistant hypertension is not simply an inconvenience. It's a prolonged, dangerous condition that significantly raises the risk of heart attack, stroke, heart failure, aortic aneurysm, and kidney failure. People with uncontrolled blood pressure live with those risks every day, despite trying to follow their doctors' advice and take their medications.
For this group, baxdrostat represents something that has been absent for a long time: a genuinely new approach, targeting a root cause rather than just a downstream effect.
One hundred million people might finally have an answer. 💊❤️
*Sources: AstraZeneca press releases · Phase 3 BaxHTN trial data · European Society of Cardiology · University of Utah Health · American Heart Association · The Guardian (August 2025) · FierceBiotech · HCPLive*
